Literature DB >> 16250208

Mouse models in preclinical studies for pachyonychia congenita.

Jiang Chen1, Dennis R Roop.   

Abstract

The similarities between the human and mouse genomes often allow researchers to make accurate predictions about the roles of their human counterparts. Because of the similar physiology between these two mammals, mice are used extensively in the laboratory to investigate the mechanisms of human diseases. Furthermore, mice provide us with the option of testing the toxicity of drugs and the safety of therapeutic approaches prior to human application. Here, we review the existing mouse models involving the keratin genes (K6a, K6b, K16, and K17) that cause the human genetic disorder pachyonychia congenita (PC). We also suggest methods to more accurately model this autosomal dominant skin condition in the mouse in order to better understand the pathophysiological processes underlying PC and importantly, provide a test-bed for testing emerging therapies in vivo.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250208     DOI: 10.1111/j.1087-0024.2005.10206.x

Source DB:  PubMed          Journal:  J Investig Dermatol Symp Proc        ISSN: 1087-0024


  3 in total

Review 1.  Pathophysiology of pachyonychia congenita-associated palmoplantar keratoderma: new insights into skin epithelial homeostasis and avenues for treatment.

Authors:  A G Zieman; P A Coulombe
Journal:  Br J Dermatol       Date:  2019-07-24       Impact factor: 9.302

2.  Inhibition of CD44 gene expression in human skin models, using self-delivery short interfering RNA administered by dissolvable microneedle arrays.

Authors:  Maria Fernanda Lara; Emilio González-González; Tycho J Speaker; Robyn P Hickerson; Devin Leake; Leonard M Milstone; Christopher H Contag; Roger L Kaspar
Journal:  Hum Gene Ther       Date:  2012-06-05       Impact factor: 5.695

Review 3.  Genetically engineered mouse models for skin research: taking the next step.

Authors:  Jiang Chen; Dennis R Roop
Journal:  J Dermatol Sci       Date:  2008-06-03       Impact factor: 4.563

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.